Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has a beta of 1.49. The stock’s Relative Strength Index (RSI) is 49.80, with weekly volatility at 12.11% and ATR at 0.20. The TNXP stock’s 52-week price range has touched low of $0.39 and a $2.46 high. Its shares traded lower over the last trading session, losing -9.15% on 02/22/21. The shares fell to a low of $1.29 before closing at $1.29. Intraday shares traded counted 21.62 million, which was 45.27% higher than its 30-day average trading volume of 39.51M. TNXP’s previous close was $1.42 while the outstanding shares total 323.91M.
Investors have identified the Biotechnology company Tonix Pharmaceuticals Holding Corp. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $429.61 million, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
Tonix Pharmaceuticals Holding Corp. (TNXP) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 62.02 million total, with 4.38 million as their total liabilities.
Having a look at the company’s valuation, the company is expected to record -0.31 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on TNXP sounds very interesting.
Is the stock of TNXP attractive?
In related news, Chief Executive Officer, LEDERMAN SETH bought 35,000 shares of the company’s stock in a transaction that recorded on Dec 30. The purchase was performed at an average price of 0.68, for a total value of 23,800. As the purchase deal closes, the Director, Treco James now bought 5,500 shares of the company’s stock, valued at 4,895. Also, Director, Bell Margaret Smith bought 5,391 shares of the company’s stock in a deal that was recorded on Aug 20. The shares were cost at an average price of 0.93 per share, with a total market value of 4,997. Following this completion of disposal, the Chief Medical Officer, SULLIVAN GREGORY M now holds 20,000 shares of the company’s stock, valued at 20,600. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.05%.